SABSSAB Biotherapeutics
About SAB Biotherapeutics
SAB Biotherapeutics (NASDAQ: SABS) pioneers groundbreaking biotechnology solutions with a focus on human antibodies. Their proprietary SAB CAP Technology™ enables the development of fully human polyclonal antibodies without human donors, promising breakthroughs in treating infectious diseases, autoimmune disorders, and cancer. The company's clinical-stage initiatives, such as human anti-thymocyte immunoglobulin (hIgG) for type 1 diabetes, underscore their commitment to advancing healthcare. With a robust immunotherapy platform and a dedication to innovation, SAB Biotherapeutics stands poised to reshape medical treatments and address critical global health challenges, offering hope for improved patient outcomes worldwide.
What is SABS known for?
Snapshot
Public US
Ownership
2014
Year founded
57
Employees
Sioux Falls, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of SAB Biotherapeutics
- Fully Human Polyclonal Antibodies: SAB Biotherapeutics specializes in the development of fully human polyclonal antibodies using their innovative technology platform.
- Immunotherapy Platform: The company offers a cutting-edge immunotherapy platform for the development of novel therapeutic solutions targeting various diseases, including infectious diseases, autoimmune disorders, and cancer.
- Clinical-Stage Therapeutics: SAB Biotherapeutics may have clinical-stage therapeutic candidates targeting specific diseases or medical conditions, such as type 1 diabetes (T1D), utilizing their human anti-thymocyte immunoglobulin (hIgG).
- Research and Development Services: SAB Biotherapeutics might offer research and development services, including collaboration opportunities with pharmaceutical companies, academic institutions, and research organizations.
- Antibody Production Technologies: The company could provide technologies and expertise related to antibody production, purification, and characterization, leveraging their proprietary methods for scalable and cost-effective manufacturing.
- Biotechnology Solutions: SAB Biotherapeutics likely offers a range of biotechnology solutions aimed at advancing medical research, drug discovery, and therapeutic development, with a focus on improving patient outcomes and addressing unmet medical needs.
SAB Biotherapeutics executive team
- Mr. Samuel J. ReichCEO & Director
- Dr. Eddie Joe Sullivan Ph.D.Co-Founder, President & Director
- Ms. Lucy ToExecutive VP & CFO
- Dr. Christoph Bausch M.B.A., Ph.D.Executive VP & COO
- Dr. Alexandra Kropotova M.B.A., M.D.Executive VP & Chief Medical Officer
- Ms. Catherine DeRoseVice President of Human Resources
- Ms. Hua Wu Ph.D.Senior Vice President of Product Development
- Dr. Carlos N. Carillo M.Sc., Ph.D.Senior Vice President of Regulatory Affairs
- Ms. Angie ParizekSenior Vice President of Clinical Operations